Body mass index at antiretroviral therapy initiation and the risk of new non-communicable disease (NCD) diagnosis or the combined endpoint of NCD/death (n=1089)

		Risk of new NCD diagnosis**			Risk of new NCD diagnosis or death†
		Adjusted Hazard Ratio	95% confidence interval	p-value	Adjusted Hazard Ratio	95% confidence interval	p-value
Baseline body mass index (BMI)*				<0.01			0.01
	20 kg/m2	1.25	(0.87, 1.80)		1.30	(0.97, 1.73)
	25 (reference)	1.00			1.00
	30	0.59	(0.40, 0.87)		0.67	(0.49, 0.93)
	35	0.78	(0.49, 1.23)		0.83	(0.56, 1.24)
Baseline CD4+count††		0.95	(0.85, 1.05)	0.31	0.91	(0.83, 0.99)	0.04
Baseline age (per 1 year increase)		1.03	(1.01, 1.05)	<0.01	1.03	(1.01, 1.05)	<0.01
Female sex		0.87	(0.51, 1.49)	0.61	1.13	(0.74, 1.72)	0.58
Nonwhite race		0.83	(0.55, 1.24)	0.36	0.96	(0.68, 1.35)	0.81
Protease inhibitor in first ART regimen		1.52	(1.01, 2.30)	0.04	1.21	(0.85, 1.71)	0.29
Year of ART initiation (per year)		0.94	(0.88, 1.00)	0.05	0.92	(0.87, 0.97)	<0.01
History of AIDS-defining event prior to starting ART		1.31	(0.79, 2.18)	0.29	1.53	(1.01, 2.31)	0.04

^*The adjusted hazard ratios represent a comparison of the point estimates of a BMI of 20, 30 and 35 kg/m² versus a BMI of 25 kg/m² extracted from the model.

^**Includes incident cardiovascular, hepatic, renal, and oncologic disease diagnoses; 111 events over a median follow-up of 2.20 years (interquartile range 0.75, 4.77); 74, 21, 16 for normal, overweight, and obese, respectively.

^†154 deaths or new NCD diagnoses; 100, 34, 20 events for normal, overweight, and obese respectively. The number of events is lower than the sum of all NCDs and deaths as only the first event was counted among those patients who died at the same time as the NCD event or after.

^††CD4+ T-cell count is square root transformed